Brendon Neuen's Publications

Jun M, Wong M, Neal Bruce, Heerspink H, Jardine M, Ohkuma T, Neuen B, Ninomiya T, Toyama T, Wada T
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
Journal Article
2019
Diabetes, Obesity and Metabolism
Li Q, Fulcher G, Bakris G, Neal Bruce, Mahaffey K, De Z, Desai M, Perkovic V, Ohkuma T, Matthews D
CANAGLIFLOZIN AND RENAL OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Conference Proceedings
2018
Spring Clinical Meeting of the National-Kidney Foundation (NKD)
Li Qiang, Jardine Meg, Mahaffey Kenneth, Fulcher Greg, Desai Mehul, Rosenthal Norm, de Zeeuw Dick, Matthews David, Deng Hsiaowei, Ohkuma Toshiaki
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program.
Journal Article
2018
Circulation
Jun M, Rogers K, Gallagher M, Jardine M, Cass A, Foote C, Neuen B, Scaria A, Sukkar L, Kang A
Infection-Related Hospitalisations Across Different Levels Of Kidney Function: Data From The Extend45 Study
Conference Paper
2018
Perkovic V, Neuen B
Reducing cardiovascular risk in people with diabetes and kidney disease
Journal Article
2018
The Medical journal of Australia
Li Q, Fulcher G, Neal Bruce, Mahaffey K, Desai M, Ohkuma T, Matthews D, Neuen B, Deng H, Rosenthal N
Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease
Journal Article
2018
Diabetes
Greenwood Alice, Gunnarsson Ronny, Neuen Brendon, Oliver Kimberley, Green Stella, Baer Richard
Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults.
Journal Article
2017
Nephrology (Carlton)
Desai Tejas, Conjeevaram Arvind, Taco Omar, Nair Sanjeev, Sridharan Sivakumar, Del Granado Rolando, Neuen Brendon, Penmatsa Krishnam, Basu Gopal, Buchkremer Florian
The birth of @ISNeducation.
Journal Article
2017
Kidney Int
Neuen B., Taylor G., Demaio A., Perkovic Vlado
Global kidney disease
Journal Article
2013
Lancet

Brendon Neuen's Publications

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis

CANAGLIFLOZIN AND RENAL OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program.

Infection-Related Hospitalisations Across Different Levels Of Kidney Function: Data From The Extend45 Study

Reducing cardiovascular risk in people with diabetes and kidney disease

Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease

Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults.

The birth of @ISNeducation.

Global kidney disease

The George Institute for Global Health

The George Institute country sites: